| Flurazepam | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Flurazepam | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Flurazepam | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | |
| Flurazepam | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | |
| Flurazepam | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | |
| Flurazepam | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | |
| Flurazepam | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Flurazepam | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Flurazepam | hsa00600 | Sphingolipid metabolism | 2.77E-02 | 3 | Q9BX95, Q8TCT0, P15289 | SGPP1, CERK, ARSA | More | |
| Flurazepam | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Flurazepam | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Flurazepam | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Flurazepam | hsa00983 | Drug metabolism - other enzymes | 1.64E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
| Flurazepam | hsa01040 | Biosynthesis of unsaturated fatty acids | 2.92E-02 | 2 | P22307, Q9H5J4 | SCP2, ELOVL6 | More | |
| Flurazepam | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Flurazepam | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Flurazepam | hsa01522 | Endocrine resistance | 4.48E-02 | 4 | P22694, Q02750, Q9UM47, P46527 | PRKACB, MAP2K1, NOTCH3, CDKN1B | More | |
| Flurazepam | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Flurazepam | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
| Flurazepam | hsa03008 | Ribosome biogenesis in eukaryotes | 6.92E-03 | 5 | Q9NYH9, P19784, P67870, P78345, Q9BVP2 | UTP6, CSNK2A2, CSNK2B, RPP38, GNL3 | More | |
| Flurazepam | hsa03013 | RNA transport | 7.94E-03 | 8 | P52298, O14893, P61326, Q7Z3B4, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, EIF3A, EIF3J, RPP38, TACC3 | More | |
| Flurazepam | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Flurazepam | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | |
| Flurazepam | hsa04014 | Ras signaling pathway | 4.04E-02 | 6 | Q02750, Q15389, P17252, P21359, P62879, P22694 | MAP2K1, ANGPT1, PRKCA, NF1, GNB2, PRKACB | More | |
| Flurazepam | hsa04015 | Rap1 signaling pathway | 3.07E-02 | 4 | P25116, Q8TEU7, P08514, P17252 | F2R, RAPGEF6, ITGA2B, PRKCA | More | |
| Flurazepam | hsa04024 | cAMP signaling pathway | 3.37E-02 | 3 | P63092, P26678, P61586 | GNAS, PLN, RHOA | More | |
| Flurazepam | hsa04064 | NF-kappa B signaling pathway | 4.92E-02 | 6 | P10415, P51617, Q13546, Q9UDY8, Q13077, P24522 | BCL2, IRAK1, RIPK1, MALT1, TRAF1, GADD45A | More | |
| Flurazepam | hsa04066 | HIF-1 signaling pathway | 4.48E-02 | 4 | P17252, Q15389, Q02750, P46527 | PRKCA, ANGPT1, MAP2K1, CDKN1B | More | |
| Flurazepam | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | |
| Flurazepam | hsa04071 | Sphingolipid signaling pathway | 3.85E-04 | 9 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2 | More | |
| Flurazepam | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | |
| Flurazepam | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Flurazepam | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
| Flurazepam | hsa04120 | Ubiquitin mediated proteolysis | 7.08E-04 | 6 | Q14145, Q13042, Q13191, P62837, Q15751, Q7Z6Z7 | KEAP1, CDC16, CBLB, UBE2D2, HERC1, HUWE1 | More | |
| Flurazepam | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
| Flurazepam | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Flurazepam | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
| Flurazepam | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.85E-03 | 9 | P07550, P22694, P18848, Q13362, Q16537, P0DP23, P17252, P10415, P20020 | ADRB2, PRKACB, ATF4, PPP2R5C, PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | |
| Flurazepam | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | |
| Flurazepam | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | |
| Flurazepam | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | |
| Flurazepam | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Flurazepam | hsa04540 | Gap junction | 2.03E-02 | 4 | P17252, P22694, P68371, Q02750 | PRKCA, PRKACB, TUBB2C, MAP2K1 | More | |
| Flurazepam | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | |
| Flurazepam | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Flurazepam | hsa04613 | Neutrophil extracellular trap formation | 1.57E-04 | 16 | P17252, O60603, P08246, Q92769, P04908, Q6FI13, Q93077, P62807, P33778, O60814, P68431, P14598, Q15080, P21462, O43315, Q16539 | PRKCA, TLR2, ELA2, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC3, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, AQP9, MAPK14 | More | |
| Flurazepam | hsa04621 | NOD-like receptor signaling pathway | 4.31E-02 | 4 | P01375, P59665, P59666, P12838 | TNF, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Flurazepam | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
| Flurazepam | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Flurazepam | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Flurazepam | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | |
| Flurazepam | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Flurazepam | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | |
| Flurazepam | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | |
| Flurazepam | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Flurazepam | hsa04720 | Long-term potentiation | 1.43E-03 | 6 | P17252, P0DP23, P51812, P22694, Q02750, Q14643 | PRKCA, CALM1, RPS6KA3, PRKACB, MAP2K1, ITPR1 | More | |
| Flurazepam | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Flurazepam | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | |
| Flurazepam | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
| Flurazepam | hsa04725 | Cholinergic synapse | 2.43E-02 | 4 | P22694, P17252, P62879, Q02750 | PRKACB, PRKCA, GNB2, MAP2K1 | More | |
| Flurazepam | hsa04726 | Serotonergic synapse | 2.09E-03 | 6 | P63092, P22694, P17252, P62873, P62879, Q02750 | GNAS, PRKACB, PRKCA, GNB1, GNB2, MAP2K1 | More | |
| Flurazepam | hsa04727 | GABAergic synapse | 2.03E-02 | 4 | P62879, P22694, O60296, P17252 | GNB2, PRKACB, TRAK2, PRKCA | More | |
| Flurazepam | hsa04912 | GnRH signaling pathway | 4.42E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | |
| Flurazepam | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Flurazepam | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | |
| Flurazepam | hsa04919 | Thyroid hormone signaling pathway | 2.22E-02 | 5 | P17252, Q02750, P22694, Q12778, Q9UM47 | PRKCA, MAP2K1, PRKACB, FOXO1, NOTCH3 | More | |
| Flurazepam | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Flurazepam | hsa04925 | Aldosterone synthesis and secretion | 1.54E-02 | 4 | Q14643, P0DP23, P17252, P20020 | ITPR1, CALM1, PRKCA, ATP2B1 | More | |
| Flurazepam | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Flurazepam | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Flurazepam | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.48E-02 | 4 | P22694, Q02750, P17252, Q9Y5Q3 | PRKACB, MAP2K1, PRKCA, MAFB | More | |
| Flurazepam | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
| Flurazepam | hsa04940 | Type I diabetes mellitus | 6.87E-04 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Flurazepam | hsa04966 | Collecting duct acid secretion | 3.15E-02 | 2 | P02730, Q9Y666 | SLC4A1, SLC12A7 | More | |
| Flurazepam | hsa04970 | Salivary secretion | 5.89E-05 | 7 | P07550, P22694, Q14643, P20020, P17252, P0DP23, P49913 | ADRB2, PRKACB, ITPR1, ATP2B1, PRKCA, CALM1, CAMP | More | |
| Flurazepam | hsa04972 | Pancreatic secretion | 1.42E-03 | 5 | Q14643, P20020, P17252, P63092, P61586 | ITPR1, ATP2B1, PRKCA, GNAS, RHOA | More | |
| Flurazepam | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
| Flurazepam | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Flurazepam | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
| Flurazepam | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Flurazepam | hsa05032 | Morphine addiction | 9.04E-05 | 5 | P62873, P48169, P78334, P63092, P32298 | GNB1, GABRA4, GABRE, GNAS, GRK4 | More | |
| Flurazepam | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Flurazepam | hsa05132 | Salmonella infection | 1.02E-03 | 10 | P51617, Q9UJU2, Q13546, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509 | IRAK1, LEF1, RIPK1, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3 | More | |
| Flurazepam | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, O60603, P49006, P51617, Q15080 | NCF1, TLR2, MARCKSL1, IRAK1, NCF4 | More | |
| Flurazepam | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | |
| Flurazepam | hsa05143 | African trypanosomiasis | 1.51E-03 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Flurazepam | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Flurazepam | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Flurazepam | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
| Flurazepam | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Flurazepam | hsa05163 | Human cytomegalovirus infection | 2.09E-02 | 4 | P62873, P61586, P63092, P61769 | GNB1, RHOA, GNAS, B2M | More | |
| Flurazepam | hsa05165 | Human papillomavirus infection | 4.71E-03 | 10 | P46527, Q02750, P35443, Q92796, Q05086, Q9UM47, P22694, Q13362, Q12778, Q13315 | CDKN1B, MAP2K1, THBS4, DLG3, UBE3A, NOTCH3, PRKACB, PPP2R5C, FOXO1, ATM | More | |
| Flurazepam | hsa05169 | Epstein-Barr virus infection | 2.54E-02 | 8 | Q92769, P04637, Q13546, P10415, P24522, O60603, P51617, P09693 | HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, IRAK1, CD3G | More | |
| Flurazepam | hsa05170 | Human immunodeficiency virus 1 infection | 6.54E-03 | 9 | P0DP23, P17252, Q13546, Q14643, P51617, O60603, P09693, P10415, Q9Y6Q5 | CALM1, PRKCA, RIPK1, ITPR1, IRAK1, TLR2, CD3G, BCL2, AP1M2 | More | |
| Flurazepam | hsa05171 | Coronavirus disease - COVID-19 | 4.47E-02 | 2 | Q9UHA3, O14786 | RSL24D1, NRP1 | More | |
| Flurazepam | hsa05202 | Transcriptional misregulation in cancer | 3.76E-02 | 7 | Q12778, Q13315, Q15744, P46527, P05164, P08246, Q9C0K0 | FOXO1, ATM, CEBPE, CDKN1B, MPO, ELA2, BCL11B | More | |
| Flurazepam | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
| Flurazepam | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Flurazepam | hsa05205 | Proteoglycans in cancer | 4.46E-03 | 9 | Q12955, Q14247, P14780, P17252, P01375, P23588, Q13635, P22694, P08962 | ANK3, CTTN, MMP9, PRKCA, TNF, EIF4B, PTCH1, PRKACB, CD63 | More | |
| Flurazepam | hsa05206 | MicroRNAs in cancer | 3.66E-02 | 6 | P46527, Q9UM47, P16070, Q13315, P17252, Q02750 | CDKN1B, NOTCH3, CD44, ATM, PRKCA, MAP2K1 | More | |
| Flurazepam | hsa05214 | Glioma | 1.00E-02 | 4 | P0DP23, P17252, P04637, P24522 | CALM1, PRKCA, TP53, GADD45A | More | |
| Flurazepam | hsa05216 | Thyroid cancer | 1.58E-03 | 5 | P01106, Q9UJU2, P04637, P24522, O75293 | MYC, LEF1, TP53, GADD45A, GADD45B | More | |
| Flurazepam | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | |
| Flurazepam | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
| Flurazepam | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | |
| Flurazepam | hsa05310 | Asthma | 1.35E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Flurazepam | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Flurazepam | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Flurazepam | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Flurazepam | hsa05330 | Allograft rejection | 1.10E-04 | 4 | P13765, P29965, P48023, P01375 | HLA-DOB, CD40LG, FASLG, TNF | More | |
| Flurazepam | hsa05332 | Graft-versus-host disease | 6.49E-05 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Flurazepam | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
| Flurazepam | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | |
| Flurazepam | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
| Flurazepam | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
